SCHEMBL6307446

SCHEMBL6307446

[O]CC(=O)NC(Cc1cccnc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
GPR132 Q9UNW8 10/20 0.54
CMKLR2 P46091 1/20 0.54
CMKLR1 Q99788 1/20 0.54
FOLH1 Q04609 1/20 0.53
ECE1 P42892 1/20 0.50
KDM4E B2RXH2 1/20 0.49
NAPRT Q6XQN6 1/20 0.47
TBXAS1 P24557 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
FDPS P14324 1/20 0.47
LMNA P02545 1/20 0.46
HPGD P15428 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6307451 0.89 GPR132 (0.54) GPR132CMKLR2CMKLR1FOLH1ECE1
SCHEMBL30387166 0.85 GPR132 (0.51) GPR132CMKLR2CMKLR1FOLH1ECE1
SCHEMBL3781118 0.84 GPR132 (0.55) GPR132CMKLR2CMKLR1FOLH1ECE1
SCHEMBL3781113 0.84 GPR132 (0.55) GPR132CMKLR2CMKLR1FOLH1ECE1
SCHEMBL30801050 0.84 GPR132 (0.55) GPR132CMKLR2CMKLR1FOLH1ECE1
SCHEMBL6192282 0.84 GPR132 (0.55) GPR132CMKLR2CMKLR1FOLH1ECE1
SCHEMBL30373349 0.84 KDM4E (0.53) GPR132CMKLR2CMKLR1FOLH1ECE1
SCHEMBL6316057 0.83 FPR2 (0.61) ECE1LMNA
SCHEMBL2495367 0.82 CYP1A2 (0.58) GPR132CMKLR2CMKLR1TBXAS1CYP1A2
SCHEMBL6374207 0.82 FPR2 (0.62) GPR132FOLH1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6906058-B2 1,5-Benzothiazepines and their use as hypolipidaemics ASTRAZENECA AB (SE) 2005-06-14 US claimed
EP-1263747-B1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS ASTRAZENECA AB (SE) 2004-11-24 EP claimed
US-20030166927-A1 1,5-Benzothiazepines and their use as hypolipidaemics ALBIREO AB (SE) 2003-09-04 US claimed
EP-1263747-A1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS AstraZeneca AB (SE) 2002-12-11 EP claimed
WO-2001066533-A1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS ASTRAZENECA AB (SE) 2001-09-13 WO claimed
US-6906058-B2 1,5-Benzothiazepines and their use as hypolipidaemics ASTRAZENECA AB (SE) 2005-06-14 US disclosed
EP-1263747-B1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS ASTRAZENECA AB (SE) 2004-11-24 EP disclosed
US-20030166927-A1 1,5-Benzothiazepines and their use as hypolipidaemics ALBIREO AB (SE) 2003-09-04 US disclosed
EP-1263747-A1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS AstraZeneca AB (SE) 2002-12-11 EP disclosed
WO-2001066533-A1 1,5-BENZOTHIAZEPINES AND THEIR USE AS HYPOLIPIDAEMICS ASTRAZENECA AB (SE) 2001-09-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030166927-A1 1,5-Benzothiazepines and their use as hypolipidaemics SLC10A2, SLC10A1, LCAT GPR132 595/4885CMKLR2 1283/4885CMKLR1 1148/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.